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Abstract 
The indolin-2-one fused-ring system and the 2,4-dimethylpyrrole unit represent key structural motifs in 
the anti-cancer drug sunitinib (Sutent®) and predecessor angiogenesis inhibitors that have undergone 
anti-cancer clinical trials (e.g. Semaxanib, SU5416). In pursuit of novel anti-angiogenic scaffolds we 
were interested in identifying whether the indolin-2-one group in these structures could be modified 
without abrogating activity. This paper describes novel condensation chemistry used to prepare a test 
series of (E) and (Z)-alkenes related to SU5416 that retain the 2,4-dimethylpyrrole unit while 
incorporating ring-opened indoline-2-ones. Unique structural characteristics were identified in the 
compounds, such as intramolecular hydrogen bonds in the (Z)-alkenes, and several examples were 
shown to possess significant anti-angiogenic activity in a rat aorta in vitro model of angiogenesis. The 
work demonstrates that the indolin-2-one moiety is not an absolute requirement for angiogenesis 
inhibition in the sunitinib/SU5416 class. 
1. Introduction 
 
Angiogenesis, the growth of new blood vessels from pre-existing vascular networks, occurs only under 
certain conditions in adults such as during wound healing, pregnancy and menstruation, but can be 
much more prevalent in pathological conditions, especially cancer. [1,2] Solid tumours which grow 
beyond 1~2 mm require angiogenesis to avoid becoming hypoxic from the effects of growth factor 
mutation-induced aberrant blood vessel formation and increased energy consumption.[3] In the absence 
of angiogenesis, solid tumours enter latent phases and rely on anaerobic metabolism for energy limiting 
their growth.[2,3] Angiogenesis is also a major contributor to metastasis as the newly formed vessels 
provide a route for tumour cells to enter the circulation.[3] Accordingly, inhibitors of angiogenesis have 
been intensely studied as anti-cancer agents and several have been approved for clinical use.[4] 
 
The first FDA-approved angiogenesis inhibitor was the vascular endothelial growth factor (VEGF)-
targeting monoclonal antibody (Mab) Bevacizumab (Avastin®; Genentech Inc., 2003), which 
continues to be used today in combination therapies against metastatic colorectal cancer,[5] non-small 
cell lung cancer[6] and metastatic breast cancer.[7] Newer VEGF-targeting agents are in various stages 
of clinical development, including, for example, VEGF-TrapR1R2 (Aflibercept; Regeneron Inc.), a 
chimeric soluble VEGF receptor that binds to and neutralises VEGF.[8] In addition to these biologics, 
small molecule receptor tyrosine kinase inhibitors (RTKIs) targeting VEGF receptors 
(VEGFR1−VEGFR3) and other kinase signalling pathways have been extensively investigated as anti-
angiogenics and several have progressed to the market. These include sunitinib 1 (Sutent®; Pfizer),[9] 
pazopanib (Votrient®, GSK),[10] sorafenib (Nexavar®; Bayer)[11] and vandetanib (Caprelsa®, 
AstraZeneca).[12] 
 
Sunitinib 1 (Figure 1) is approved for the treatment of highly vascularised renal cell carcinomas,[13] 
gastrointestinal stromal tumours[14] and pancreatic neuroendocrine tumours.[15] Its mechanism of action 
involves inhibition of at least eight different receptor tyrosine kinases, including VEGF1-VEGF3, 
platelet-derived growth factor receptors (PDGFR and PDGFR), stem cell factor receptor (Kit), FLT-
3 and colony-stimulating factor-1 receptor (CSF-1R).[16] During development the indolin-2-one 
(oxindole) and 2,4-dimethylpyrrole portions of Sunitinib 1 were identified as key pharmacophores and 
were retained throughout med-chem optimisation efforts. Several other closely related compounds 
which contain these groups were also (and continue to be) evaluated in clinical trials.[17] For example, 
the structurally simpler sunitinib predecessor semaxanib (SU5416) 2 (Figure 1) underwent a Phase III 
clinical trial for advanced colorectal cancer. 
 




In pursuit of novel and patentable anti-angiogenic scaffolds, we hypothesised that in spite of its 
perceived importance the indolin-2-one moiety may not be essential for anti-angiogenic activity in the 
sunitinib/SU5416 class. The hypothesis has been explored in the current work using a test series of 
SU5416-like alkenes that attach the 2,4-dimethylpyrolle unit to ring-opened indoline-2-ones  (i.e. 
compounds (Z)-3a, (E)-3b − (Z)-10a, (E)-10b, Figure 1). This paper details the synthesis of the series 
using novel condensation chemistry, describes some of the unique structural characteristics of the 
alkenes, as identified by NMR spectroscopy and x-ray crystallography, and reports that several 
members show significant anti-angiogenic activity in a rat aorta in vitro model of angiogenesis. 
 
2. Chemistry 
Initial synthetic efforts aimed to identify a general condensation reaction that could provide access to 
the target alkenes. In the reported syntheses of sunitinib 1, SU5416 2 and related indolin-2-ones, the 
base indoline-2-ones and requisite N-unsubstituted pyrrole-2-carboxaldehydes were condensed by 
refluxing the two components in ethanol with piperidine.[18] Attempts to adapt this procedure to the 
condensation of the model substrate ethyl-2-(2-nitrophenyl)-acetate 13 and 3,5-dimethylpyrrole-2-
carboxaldehyde 11 failed to yield any of the desired alkenes (Z)-3a or (E)-3b). Other Knoevenagel or 
Perkin-type condensations attempted with 13 and 11 using various bases and solvents and under a 
variety of conditions were similarly unsuccessful. At this point it was reasoned that the aldehyde in 11 
was unreactive due to a combination of steric hindrance from the neighbouring pyrrole 3-Me group and 
because electron donation from the pyrrole nitrogen into the aldehyde was reducing its electrophilic 
character. It was postulated that a small electron withdrawing group attached to the pyrrole nitrogen 
should increase the aldehyde’s reactivity without increasing steric hinderance. Attaching electron 
withdrawing groups to pyrrole nitrogens has previously been shown to activate aldehydes at the 2-
position.[19,20] Accordingly, N-methylcarbamoyl pyrrole-2-carboxaldehyde 12 was prepared in 86% 
yield by acylating the potassium salt of 11 (formed by N-deprotonation of 11 with KH in THF at 0 oC) 





Scheme 1. Synthesis of N-methylcarbamoyl pyrrole aldehyde 12.a 
 
aReagents and conditions: (a) (i) KH, THF, 0 oC, (ii) CH3OCOCl, 2 h, (86%). 
 
Stirring ethyl-2-(2-nitrophenyl)-acetate 13 with 12 in refluxing THF in the presence of K2CO3 and 18-
crown-6 (Method a, Figure 2) was found to directly afford the pyrrole N-deprotected Knoevenagel 
condensation products (Z)-3a (42%) and (E)-3b (35%). Similar yields of the desired N-deprotected (Z) 
and (E)-alkenes were obtained directly from reactions of 12 with methyl-2-(2-nitrophenyl)-acetate 14 
and allyl-2-(2-nitrophenyl)-acetate 15 (i.e. (Z)-4a, (E)-4b and (Z)-5a, (E)-5b, respectively). The 
condensation reactions did not proceed when the N-methyl carbamoyl group of 12 was replaced with 
either N-ethyl or N-tButyl carbamates, possibly due to increased steric hindrance around the aldehyde. 
 
Use of N-alky- or N-aryl-2-(2-nitrophenyl)-acetamides in place of 2-(2-nitrophenyl)-acetic esters led to 
reduced yields of the Z-isomers and none or very low yields of the E-isomers. Nevertheless, several 
amides were able to be isolated in sufficient quantity and purity (> 95% by 1H NMR) for 
characterisation and angiogenesis inhibition testing. Use of N-Ethyl-2-(2-nitrophenyl)-acetamide 16 in 
the reaction afforded a 21% yield of (Z)-6a without formation of any (E)-6b. N-Phenyl-2-(2-
nitrophenyl)-acetamide 17 and N-benzyl-2-(2-nitrophenyl)-acetamide 18 yielded 22% and 16% yields, 
respectively, of alkenes (Z)-7a and (Z)-8a, with less than 5% of the trans-isomers (E)-7b and (E)-8b 
being isolated. All alkenes except (E)-7b and (E)-8b were tested for angiogenesis inhibition. 
 
 



















#Ester/ Amide R1 R2
Reaction
Conditions Product, Yield
13 - 20 12




14 NO2 OMe a (Z)-4a, 36% (E)-4b, 40%
15 NO2 OAll a (Z)-5a, 41% (E)-5b, 33%
(E)-3b (E)-10b
16 NO2 NHEt a (Z)-6a, 21% (E)-6b, 0%
17 NO2 NHPh a (Z)-7a, 22% (E)-7b, <5%*
18 NO2 NHBn a (Z)-8a, 16% (E)-8b, <5%*
19 H OEt b (Z)-9a, 0% (E)-9b, 32%
20 Cl OEt b (Z)-10a, 5% (E)-10b, 41%
*Compounds could not be isolated in pure form. #Esters 13 15,19,20 were synthesised
by refluxing the phenylacetic acids in the requisite alcohol (as solvent) with H2SO4 (cat.).
Amides 16 18 were obtained by stirring 2-nitro-phenylacetic acid with the requisite amines
under standard solution phase peptide coupling conditions (i.e. HBTU/DIPEA in CH2Cl2).  
aReagents and conditions: (a) K2CO3, 18-crown-6, THF, reflux, 16 h; (b) LDA, THF, -78 




In our structure-activity study it was of interest to establish the importance of the 2-nitro group for 
angiogenesis inhibition. Alkenes (Z)-9a, (E)-9b, (Z)-10a and (E)-10b were targeted for this purpose. 
However, attempts to perform the condensation (Figure 2, Method a) with 12 and either ethyl-2-
phenylacetate 19 or ethyl-2-(2-chlorophenyl)-acetate 20 were unsuccessful, thus highlighting the 
requirement for the ortho-nitro group in this reaction. Switching to the stronger base LDA and carrying 
the reaction out with ethyl-2-phenylacetate 19 in THF at -78 oC (Figure 2, Method b) afforded a 32% 
yield of the trans alkene (E)-9b while none of the cis alkene (Z)-9a was formed. Applying the same 
procedure with 2-(2-chlorophenyl)-acetate 20 yielded 41% of (E)-10b and 5% of the cis isomer (Z)-
10a. 
 
Figure 3. (a) cis-stereochemistry was confirmed in (Z)-3a – (Z)-10a by the presence of an NOE 
between the vinylic proton and ortho proton on their respective phenyl rings. (b) Comparison of the 
pyrrole NH chemical shift values in the 1H NMR spectra of cis-alkenes (Z)-3a – (Z)-10a and trans-
alkenes (E)-3b – (E)-10b. The downfield-shifted signals in the cis-series are indicative of 














































Cis-stereochemistry was confirmed in alkenes (Z)-3a – (Z)-10a from 2D-NOESY spectra which in all 
cases showed NOE cross-peaks between the vinylic proton and the ortho proton on the phenyl ring 
(Figure 3a). A second feature common to all cis-isomers was a downfield chemical shift of the pyrrole 
NH signals (11.80 – 12.91 ppm) in their 1H NMR spectra relative to the corresponding trans-isomers 
(6.47 – 6.87 ppm, Figure 3b). These strongly deshielded signals suggested the presence of 
intramolecular hydrogen bonds in the cis-alkenes between the pyrrole NH and carbonyl oxygen 
atoms.[21] Furthermore, the cis-isomers were all observed to be significantly less polar than their 
corresponding trans-isomers (by TLC) which, in addition to simplifying purification by silica-gel 
column chromatography, supported the presence of the hydrogen bonds. The presence of an 
intramolecular hydrogen bond in allyl ester (Z)-5a was eventually confirmed (in the solid state) by x-
ray crystallography (Figure 4a). It is noteworthy that analogous hydrogen bonds are found in SU5416 2 
and related indolin-2-one-based angiogenesis inhibitors which contain (Z)-alkenes.[22] 
 
The 1H NMR spectrum of (E)-3b displayed an unusual pair of doublet-of-quartet signals at 4.10 ppm 
and 4.23 ppm (total integration 2H) suggesting the presence of diastereotopic ethyl ester CH2 protons 
(Supplementary Data, Figure S1 (b)). In contrast, the CH2 group of (Z)-3a displayed the expected first-
order quartet at 4.12 ppm. (Supplementary Data, Figure S1 (a)). Complex methylene signals were 
similarly observed for the allyl ester methylene CH2 of (E)-5b (2 x doublet-of-doublets at 4.59 ppm and 
4.64 ppm) and the ethyl ester CH2 group of (E)-10b (2 x quartets at 4.18 ppm and 4.25 ppm). Such 
observations are consistent with the di-substituted phenyl rings of these compounds being unable to 
freely rotate about the ipso Ar-C bond due to a steric clash between the bulky ortho-phenyl ring 
substituents (i.e. ortho-NO2 in (E)-3b and (E)-5b and ortho-Cl in (E)-10b) and the pyrrole ring located 
on the same side of the alkene double bond (Supplementary Data, Figure S1 (c)). The restricted rotation 
and resulting axial double-bond chirality in these “overcrowded” alkenes explains the presence of 
diastereotopic CH2 signals in the 
1H NMR spectra. That the CH2 group of (E)-9b (which contains no 
aryl ortho-substituent) produced a simple quartet at 4.22 ppm supports this explanation, as does the 
appearance of the CH2 groups of cis-alkenes (Z)-5a, (Z)-6a and (Z)-10a as first-order quartets 
(integration 2H), and the benzyl CH2 group of (Z)-8a as a simple doublet (integration 2H). 
 
Single crystal x-ray structures were obtained for the pair of allyl esters (Z)-5a and (E)-5b (Figure 4). 
The solid-state structure of (Z)-5a provided clear evidence for an intramolecular hydrogen bond 
stabilising a pseudo-7-membered ring within its structure. The inter-atomic distance between the 
pyrrole nitrogen and the carbonyl oxygens atom in the crystal structure was very short (2.7 Å) 
suggesting that the hydrogen bond in (Z)-5a is relatively strong.[21] The x-ray structure of (E)-5b 
showed no intramolecular hydrogen bonds. 
 
Figure 4. ORTEP plots of allyl esters (a) (Z)-5a and (b) (E)-5b. An intramolecular hydrogen bond was 
observed in (Z)-5a between the pyrrole N-H and carbonyl oxygen atoms (N7 to O20 distance = 2.7 Å).  
 
 
3. Angiogenesis Inhibition 
The alkenes were tested for anti-angiogenic effects using our previously reported rat aorta in vitro 
model of angiogenesis (Figure 5).[23] In this assay, thoracic aortic sections are excised from female 
Fischer 344 rats and suspended in a fibrin gel matrix in 48-well plates. A minimum of six replicate 
cultures for each compound treatment (at each concentration) are prepared. The cultures are fed on Day 
4 and vessel outgrowths from the rings measured on Day 5. Angiogenesis is visualised under a 
microscope (40 x magnification) and quantified manually as the percentage of the field of view (FOV) 
around the vessel fragment occupied by new vessel outgrowths (i.e. FOV %). Under these conditions, 
absence of test compound produces 85.7% FOV occupancy (Figure 5; Control: no compound). 
 
Two positive controls PI-88 and SU5416 2 were included in the assays. PI-88 is a highly sulfated 
oligosaccharide-based angiogenesis inhibitor[24] currently undergoing Phase III clinical trials as a single 
treatment following cancer surgery in subjects with hepatitis virus-related hepatocellular carcinoma.[25] 
At 100 g/mL, PI-88 reduced FOV occupancy to 39.2%. SU5416 2 produced an unusual response 
where greater inhibition of angiogenesis was observed at 10 g/mL (FOV occupancy 9.7%) than at 100 
g/mL (FOV occupancy 30.6%), while 61.4% FOV occupancy was observed at 1 g/mL. Small 
crystals observed in wells containing 100 g/mL SU5416 2 suggested that its low solubility in the 
medium may have caused the poor dose dependency. 
 
Ethyl and methyl esters (Z)-3a, (E)-3b, (Z)-4a and (E)-4b were found to completely inhibit 
angiogenesis at 100 g/mL. At 10 g/mL (E)-3b continued to show complete inhibition whereas the 
other three esters all showed significantly diminished effects at this concentration. At 1 g/mL, the four 
esters showed either minimal effects (< 20% difference relative to negative control) or no activity. 
Surprisingly, the cis-allyl ester (Z)-5a showed the same level of inhibition at both 100 g/mL and 10 
g/mL (FOV occupancy 28.3% and 29.3%, respectively) but no activity at 1 g/mL. For the trans-allyl 
ester (E)-5b, strong activity was observed at 100 g/mL (FOV occupancy 8.3%) but this activity was 
completely abolished at 10 g/mL. We conclude from the data that (E)-3b is the most active of the 2-
nitrophenylacetic ester series. 
 
The cis-ethylamide (Z)-6a showed reduced effects (FOV occupancy 51.7% at 100 g/mL, inactive at 
10 g/mL) relative to (Z)-3a, indicating that directly substituting the ester group for an amide is 
detrimental for activity. Observing that amides (Z)-7a and (Z)-8a were inactive at 100 g/mL supported 
this conclusion. Removal of the NO2 group from the phenyl ring was found to completely abolish 
activity (i.e. (E)-9b vs (E)-3b). Interestingly, replacing the NO2 group with Cl had no effect on activity 
at 100 g/mL, with both (E)-10b and (E)-3b completely inhibiting angiogenesis, but at 10 g/mL (E)-
10b showed no activity. 
 
 
Figure 5. Inhibition of angiogenesis by alkenes (Z)-3a, (E)-3b − (Z)-10a, (E)-10b relative to negative 
control (no compound) and positive controls PI-88[24] (100 g/mL) and SU5416 2. Female Fischer 344 
rat thoracic aortic sections were cultured in a gel fibrin matrix in 48-well plates in the presence/absence 
of compounds. Cultures were fed on Day 4 and vessel outgrowths measured on Day 5.[23] Wells were 
visualised under 40 x magnification and the percentage of the field of view (FOV) occupied by vessel 
outgrowths reported as FOV occupancy (%). Negative control (no compound, unshaded bar) showed 
85.7 % FOV occupancy. Compounds showing little or no activity at higher concentrations were not 
tested at lower concentration(s). Data represent the mean FOV occupancy (%) generated from at least 
six replicate cultures of each test compound at each concentration tested. (See Supplementary Data 




Visual inspection of the assay wells on Day 5 revealed that outgrowths sprouting from rings 
cultured in the presence of SU5416 2 (100 g/mL) differed markedly in morphology from those 
sprouting from control rings (no compound) or from rings cultured in the presence of PI-88 (100 
g/mL) or alkenes (e.g. (Z)-3a, 100 g/mL) (Figure 6). While the outgrowths from the control rings 
and rings grown in the presence of PI-88 or alkenes showed normal morphology, outgrowths from the 
SU5416 2 treated rings consisted of fine hair-like structures which lacked a visible lumen. At lower 
concentrations of SU5416 2 (10 g/mL) the outgrowths showed normal morphology. 
 
Figure 6. Morphology of vessel outgrowths from rat aortic rings cultured in the presence of: (a) 
Control (no compound), (b) PI-88 (100 g/mL) and (c) SU5416 2 (100 g/mL). The outgrowths from 
control rings and rings grown in the presence of PI-88 (and (Z)-3a; image not shown) appeared normal 
whereas rings cultured in the presence SU5416 2 produced fine hair-like outgrowths with no lumen. 
 
 
4. Concluding Remarks 
In summary, a novel series of alkenes (Z)-3a, (E)-3b − (Z)-10a, (E)-10b was synthesised to test the 
hypothesis that anti-angiogenic activity can be retained in structures related to semaxanib (SU5416) 2, 
a structurally simpler predecessor of the FDA approved drug sunitinib, when the indolin-2-one moiety 
is modified through ring opening. The 2,4-dimethylpyrrole portion of SU5416 2 was retained in the test 
compounds to strengthen conclusions regarding the importance of the indoline-2-one group. In vitro 
angiogenesis inhibition assays revealed that several of the alkene esters, including both (Z) and (E)-
isomers, showed significant anti-angiogenic effects. Compound (E)-3b emerged as the most potent 
showing complete inhibition of angiogenesis at 10 g/mL. The work provides evidence that the 
indolin-2-one moiety is not essential for anti-angiogenic activity in the sunitinib/SU5416-type class. 
 
The novel condensation chemistry developed to access the target series has scope for wider 
explorations. For example, while the ortho-NO2 group was found to be necessary for successful 
reactions with phenylacetic esters and amides it would be of interest to explore whether this group can 
be moved to the meta or para positions on the phenyl ring and whether it can be replaced altogether 
with other electron withdrawing groups. Additionally, it is likely that 12 could be useful as a 3,5-
dimethylpyrrole-2-carboxaldehyde surrogate in condensation reactions with carbanions derived from 
substrates other than phenylacetic esters and amides. It is also tempting to speculate that pyrrole N-
methyl carbamoylation might be a more generally useful tactic in condensation reactions with other 
pyrrole-2-carboxaldehydes where either enhanced aldehyde reactivity and/or pyrrole N-protection is 
required. 
 
5. Experimental Section 
5.1. Chemistry.  
3,5-Dimethylpyrrole-2-carboxaldehyde 11 was purchased from Sigma-Aldrich. Semaxanib (SU5416) 2 
was synthesised in-house using a novel (unpublished) procedure. The spectroscopic data for the 
synthesised Semaxanib was identical in all respects to that reported in the literature.[22] Anhydrous 
tetrahydrofuran (THF) was freshly distilled from sodium benzophenone ketyl. Anhydrous CH2Cl2 was 
freshly distilled from CaH2. All other solvents were of analytical reagent (AR) grade and used without 
further purification. The term petroleum spirit refers to petroleum spirit within the boiling range 40 – 
60 oC. Column chromatography was performed using silica gel 60 (230–400 mesh, Merck). Reaction 
monitoring by thin layer chromatography (TLC) was carried out using Merck Silica Gel 60 F254 (0.2 
mm) plates. Compounds were visualized by examination under UV light and/or by staining with 
cerium ammonium molybdate. 1H and 13C NMR spectra were recorded on a Varian-Inova-500 MHz 
spectrometer. Chemical shifts () are expressed in ppm relative to tetramethylsilane (0 ppm). Signal 
splitting patterns are described as singlet (s), broad singlet (br s), doublet (d), triplet (t), broad triplet (br 
t), multiplet (m) or a combination of the above. IR spectra were recorded using a Nicolet Avatar 360 
FT-IR spectrometer with characteristic absorption bands reported in wavenumbers [cm-1]. High 
resolution electrospray ionisation mass spectra were recorded using a factory modified Waters QToF 
Ultima Mass Spectrometer (Wyntheshawe, UK). Melting points were determined using a Reichert 
melting point apparatus and are uncorrected. 
 
Methyl 2-formyl-3,5-Dimethyl-1H-pyrrole-1-carboxylate (12): 3,5-dimethylpyrrole-2-
carboxaldehyde 11 (1.47 g, 11.9 mmol) in anhydrous THF (10 mL) was added dropwise over 10 min to 
a stirring suspension of potassium hydride (0.57 g, 14.3 mmol) in dry THF (50 mL) under N2 at 0 ºC. 
Following complete addition the mixture was allowed to stir at 0 ºC for a further 30 minutes. Methyl 
chloroformate (2.48 g, 26.2 mmol) diluted in anhydrous THF (10 mL) was then added dropwise to the 
stirring mixture at 0 ºC over ten minutes. The reaction was allowed to warm slowly to room 
temperature and stirred for a further 2 hours while monitoring by TLC analysis (petroleum 
spirit:acetone, 80:20). After complete consumption of starting material the reaction was quenched with 
ice-cold H2O (30 mL) and stirred for 15 min. The crude mixture was extracted with EtOAc (3 x 25 mL) 
and the combined organic extracts washed with H2O (25 mL) and brine (25 mL) before drying over 
anhydrous MgSO4 and concentrating in vacuo. The crude product was purified by silica-gel column 
chromatography using a gradient from 100:0 to 95:5 petroleum spirit:acetone to provide 12 (1.83 g, 
85%) as a white crystalline solid. Rf = 0.53 (80:20 petroleum spirit:acetone), m.p. 44-45 
ºC; 1H NMR 
(500 MHz, CDCl3, ):  2.34 (s, 3H), 2.42 (s, 3H), 4.00 (s, 3H), 5.93 (s, 1H), 10.03 (s, 1H); 13C NMR 
(125 MHz, CDCl3):  12.9, 15.2, 54.3, 115.9, 130.3, 135.8, 138.2, 151.5, 181.2; IR (neat): ν(cm-1) = 
1730, 1650, 1496, 1451, 1326, 1153, 765 cm-1; HRMS-ESI: m/z [M+H]+ calcd for C9H11NO3  
182.0812, observed 182.0817. 
 
General method for the synthesis of 2-phenylacetic esters 13-15, 19, 20: A solution of the requisite 
2-phenylacetic acid (~ 3 g) in the appropriate alcohol (40 mL) with 5 drops of concentrated sulfuric 
acid added was stirred at reflux under N2. Upon complete disappearance of starting material (TLC; 
petroleum spirit:acetone, 70:30) the reaction mixture was allowed to cool to room temperature before 
removing the alcohol by evaporation in vacuo. The crude residue was diluted with EtOAc (50 mL), 
added to a separating funnel and washed with saturated aqueous Na2CO3 (30 mL), H2O (3 x 25 mL), 
and brine (30 mL). The organic layer was then dried over anhydrous MgSO4 and concentrated in 
vacuo.  
 
Ethyl-2-(2-nitrophenyl)-acetate (13): 97%, white crystalline solid; m.p. 61-63 oC; 1H NMR (500 
MHz, CDCl3):  1.16 (t, 3H, J = 7.0 Hz), 3.93 (s, 2H), 4.07 (q, 2H, J = 7.0 Hz), 7.28 (d, 1H, J = 7.5 
Hz), 7.38 (t, 1H, J = 8.0 Hz), 7.50 (t, 1H, J = 7.5 Hz), 7.99 (d, 1H, J = 8.0 Hz); 13C NMR (125 MHz, 
CDCl3):  13.7, 39.4, 60.9, 124.9, 128.2, 129.5, 132.9, 133.2, 148.5, 170.0. HRMS-ESI: m/z [M+H]+ 
calcd for C10H12NO4  210.0761, observed 210.0757. 
 
Methyl-2-(2-nitrophenyl)-acetate (14): 97%, pale yellow oil; 1H NMR (500 MHz, CDCl3):  3.68 (s, 
3H), 4.00 (s, 2H), 7.34 (d, 1H, J = 8.0 Hz), 7.45 (t, 1H, J = 8.0 Hz), 7.57 (t, 1H, J = 8.0 Hz), 8.08 (d, 
1H, J = 8.0 Hz); 13C NMR (125 MHz, CDCl3):  39.8, 52.5, 125.5, 128.9, 133.5, 133.6, 133.8, 148.9, 
170.6. HRMS-ESI: m/z [M+H]+ calcd for C9H10NO4  196.0604, observed 196.0615. 
 
Allyl-2-(2-nitrophenyl)-acetate (15): 88%, pale yellow oil; 1H NMR (500 MHz, CDCl3):  4.04 (s, 
2H), 4.60 (dd, 2H, J = 1.5, 4.5 Hz), 5.21 (dd, 1H, J = 1.5, 10.0 Hz), 5.28 (dd, 1H, J = 1.5, 17.0 Hz), 
5.89 (m, 1H), 7.35 (d, 1H, J = 7.5 Hz), 7.46 (t, 1H, J = 7.5 Hz), 7.58 (t, 1H, J = 7.5 Hz), 8.09 (d, 1H, J 
= 7.5 Hz); 13C NMR (125 MHz, CDCl3):  39.8, 66.0, 118.7, 125.4, 128.8, 132.0, 133.6, 133.8, 148.5, 
169.8. ESI-MS: 222.3 [M + H]+. HRMS-ESI: m/z [M+H]+ calcd for C11H12NO4  222.0761, observed 
222.0733. 
 
Ethyl-2-phenylacetate (19): 80%, pale yellow oil; 1H NMR (500 MHz, CDCl3):  1.23 (t, 3H, J= 7.0 
Hz), 3.56 (s, 2H), 4.13 (q, 2H, J = 7.0 Hz), 7.29 (m, 5H); 13C NMR (125 MHz, CDCl3):  14.2, 41.4, 
60.8, 128.0, 134.3, 171.6. HRMS-ESI: m/z [M+H]+ calcd for C10H13O2  165.0910, observed 165.0914. 
 
Ethyl-2-(2-chlorophenyl)-acetate (20): 71%, pale yellow oil; 1H NMR (500 MHz, CDCl3):  1.20 (t, 
3H, J = 7.0 Hz), 3.71 (s, 2H), 4.12 (q, 2H, J =7.0 Hz), 7.23 (m, 4H); 13C NMR (125 MHz, CDCl3):  
14.0, 38.9, 60.7, 128, 132.4, 134.3, 170.5. HRMS-ESI: m/z [M+H]+ calcd for C10H12ClO2  199.0520, 
observed 199.0526. 
 
General procedure for the synthesis of N-alkyl/aryl-2-(2-nitrophenyl)-acetamides 16-18: A dry 
round-bottom flask under N2 was charged with 2-nitrophenylacetic acid (324 mg, 1.79 mmol), amine 
(2.42 mmol), HBTU (709 mg, 1.87 mmol) and CH2Cl2 (10 mL) before adding DIPEA (3.85 mmol). 
The solution was stirred at room temperature while monitoring by TLC analysis (petroleum 
spirit:acetone, 80:20). Upon complete consumption of starting material the reaction was diluted with 
CH2Cl2 (30 mL) and washed with 5% HCl (3 x 25 mL), saturated aqueous Na2CO3 (3 x 25 mL) and 
brine (30 mL). The organic layer was dried over anhydrous MgSO4 and concentrated to afford the pure 
amide. 
 
N-Ethyl-2-(2-nitrophenyl)-acetamide (16): 57%, white amorphous solid; m.p. 137-139 oC; 1H NMR 
(500 MHz, CDCl3):  1.13 (t, 3H, J = 7.0 Hz), 3.29 (q, 2H, J = 7.0 Hz), 3.81 (s, 2H), 5.80 (br s, 1H), 
7.45 (t, 1H, J = 7.5 Hz), 7.50 (d, 1H, J = 7.5 Hz), 7.60 (t, 1H, J = 7.5 Hz), 8.02 (d, 1H, J = 8.5 Hz); 13C 
NMR (125 MHz, CDCl3):  15.0, 35.0, 41.1, 125.3, 128.6, 130.7, 133.6, 133.8, 149.1, 169.0. HRMS-
ESI: m/z [M+H]+ calcd for C10H13N2O3  209.0921, observed 209.0924. 
 
N-Phenyl-2-(2-nitrophenyl)-acetamide (17): 95%, off-white amorphous solid; m.p. 141-143 oC; 1H 
NMR (500 MHz, CDCl3):  4.03 (s, 2H), 7.08 (t, 1H, J = 7.5 Hz), 7.28 (t, 2H, J = 7.5 Hz), 7.47 (m, 
3H), 7.54 (d, 1H, J = 7.0 Hz), 7.61 (t, 1H, J = 7.5 Hz), 7.82 (br s, 1H), 8.05 (d, J = 8.5 Hz); 13C NMR 
(125 MHz, CDCl3):  41.9, 119.9, 124.4, 125.2, 128.6, 128.9, 130.0, 133.4, 133.7, 167.2. HRMS-ESI: 
m/z [M+H]+ calcd for C14H13N2O3  257.0921, observed 257.0929. 
 
N-Benzyl-2-(2-nitrophenyl)-acetamide (18): 95%, off-white amorphous solid; m.p. 136-138 oC; 1H 
NMR (500 MHz, CDCl3):  3.88 (s, 2H), 4.45 (d, 2H, J = 6 Hz), 6.12 (br s, 1H), 7.26 (t, 3H, J = 8.0 
Hz), 7.31 (t, 2H, J = 7.5 Hz), 7.45 (t, 1H, J = 7.5 Hz), 7.51 (d, 1H, J = 7.5 Hz), 7.60 (t, 1H, J = 7.5 Hz), 
8.04 (d, 1H, J = 8.5 Hz); 13C NMR (125 MHz, CDCl3):  40.9, 43.8, 125.1, 127.5, 127.6, 128.5, 128.7, 
130.2, 133.5, 133.6, 137.9, 148.9, 169.0. HRMS-ESI: m/z [M+H]+ calcd for C15H15N2O3  271.1077, 
observed 271.1065. 
 
General method for condensation reactions to produce alkenes (Z)-3a, (E)-3b − (Z)-8a, (E)-8b: 
Method a: To a dry round bottom flask under N2 was added anhydrous potassium carbonate (1.205 g, 
8.73 mmol) in dry THF (15 mL) followed by 18-crown-6 (0.575 g, 2.18 mmol). The mixture was 
stirred at room temperature for 10 minutes before adding a solution of the appropriate 2-(2-
nitrophenyl)-acetate/acetamide (4.36 mmol) in dry THF (10 mL) and heating at reflux for 3 hours. 
Methyl 2-formyl-3,5-dimethyl-1H-pyrrole-1-carboxylate 12 (0.789 g, 4.36 mmol) was diluted in dry 
THF (8 mL) and added drop wise over 15 minutes to the stirring solution. The mixture was then heated 
at reflux for a further 16 hours. The reaction was quenched with water (30 mL), transferred to a 
separating funnel and extracted with EtOAc (3 x 40 mL). The combined organic layer was washed with 
saturated aqueous Na2CO3 (2 x 50 mL) and brine (2 x 50 mL), dried over anhydrous MgSO4 and 
concentrated in vacuo. The crude product was purified by silica-gel column chromatography using a 
petroleum spirit:acetone gradient of 100:0 to 80:20 to provide mixtures of the (Z) and (E)-isomers. 
 
(Z)-Ethyl 3-(3,5-dimethyl-1H-pyrrol-2-yl)-2-(2-nitrophenyl)-acrylate ((Z)-3a): 42%, red crystalline 
solid; m.p. 124-126 ºC; Rf = 0.50 (70:30 hexane:acetone); 
1H NMR (500 MHz, CDCl3):  1.13 (t, 3H, J 
= 7.0 Hz), 2.17 (s, 3H), 2.35 (s, 3H), 4.12 (q, 2H, J = 7.0 Hz), 5.90 (s, 1H), 6.82 (s, 1H), 7.43 (m, 1H), 
7.62 (t, 2H, J = 8.0 Hz), 8.02 (d, 1H, J = 8.0 Hz), 11.89 (br s, 1H); 13C NMR (125 MHz, CDCl3):  
13.7, 14.1, 29.9, 62.1, 111.5, 112.7, 124.1, 124.6, 127.8, 129.9, 131.5, 132.5, 133.5, 134.3, 137.5, 
148.5, 163.8; IR (neat): ν(cm-1) = 3275, 2354, 1684, 1577, 1569, 1544, 1518, 1367, 1335, 1319, 1262, 
1196, 1153, 1026, 830, 789, 710 cm-1; HRMS-ESI: m/z [M+H]+ calcd for C17H19N2O4: 315.1339,  
observed 315.1350. 
 
(E)-Ethyl 3-(3,5-dimethyl-1H-pyrrol-2-yl)-2-(2-nitrophenyl)-acrylate ((E)-3b): 35%, red crystalline 
solid; m.p. 117-119 ºC; Rf = 0.26 (70:30 hexane:acetone); 
1H NMR (500 MHz, CDCl3):   1.19 (t, 3H, 
J = 7.0 Hz), 1.95 (s, 3H), 2.19 (s, 3H), 4.10 (dq, 1H, J = 4.0, 7.0 Hz), 4.23 (dq, 1H, J = 3.7, 7.0 Hz), 
5.74 (s, 1H), 6.80 (br s, 1H), 7.49 (t, 1H, J = 7.5 Hz), 7.59 (t, 1H, J = 7.5 Hz), 7.67 (t, 1H, J = 7.5 Hz), 
7.75 (s, 1H), 8.19 (d, 1H, J = 7.5 Hz); 13C NMR (125 MHz, CDCl3):  11.3, 13.2, 14.1, 60.8, 110.7, 
116.6, 123.4, 125.6, 127.2, 129.2, 130.1, 132.5, 133.3, 133.4, 136.7, 149.2, 166.6; IR (neat): ν(cm-1) = 
3447, 3421, 1700, 1618, 1607, 1564, 1518, 1338, 1180, 1147, 1093, 795 cm-1; HRMS-ESI: m/z 
[M+H]+ calcd for C17H19N2O4: 315.1339,  observed 315.1337. 
 
(Z)-Methyl 3-(3,5-dimethyl-1H-pyrrol-2-yl)-2-(2-nitrophenyl)-acrylate ((Z)-4a): 36%, red 
crystalline solid; m.p. 66-68 ºC; Rf = 0.47 (80:20 petroleum spirit:acetone); 
1H NMR  (500 MHz, 
CDCl3):  2.14 (s, 3H), 2.32 (s, 3H), 3.61 (s, 3H), 5.88 (s, 1H), 6.79 (s, 1H), 7.40 (d, 1H, J = 7.5 Hz), 
7.41 (t, 1H, J = 7.5 Hz), 7.59 (t, 1H, J = 7.5 Hz), 8.00 (d, 1H, J = 7.5 Hz), 11.82 (br s, 1H); 13C NMR 
(125 MHz, CDCl3):  11.8, 13.9, 52.0, 111.6, 114.0, 124.5, 124.6, 128.0, 131.5, 134.4, 137.3, 148.5, 
168.2; IR (neat): ν(cm-1) = 3455, 1691, 1603, 1555, 1522, 1430, 1343, 1222, 1190, 1172, 1149, 789, 
718 cm-1; HRMS-ESI: m/z calcd for C16H17N2O4 [M + H]
+ 301.1183; observed 301.1185. 
 
(E)-Methyl 3-(3,5-dimethyl-1H-pyrrol-2-yl)-2-(2-nitrophenyl)-acrylate ((E)-4b): 40%, red 
crystalline solid; m.p. 90-93 ºC; Rf = 0.36 (80:20 petroleum spirit:acetone); 
1H NMR  (500 MHz, 
CDCl3):  1.95 (s, 3H), 2.20 (s, 3H), 3.70 (s, 3H), 5.74 (s, 1H), 6.74 (br s, 1H), 7.50 (d, 1H, J = 7.5 Hz), 
7.61 (t, 1H, J = 7.5 Hz), 7.68  (t, 1H, J = 7.5 Hz), 7.75 (s, 1H), 8.20 (d, 1H, J = 7.5 Hz); 13C NMR (126 
MHz, CDCl3):  11.6, 13.4, 52.3, 111.0, 116.3, 123.6, 125.5, 127.6, 129.4, 130.6, 132.7, 133.4, 133.8, 
134.1, 149.4, 167.4; IR (neat): ν(cm-1) = 3293, 1689, 1570, 1544, 1518, 1432, 1365, 1334, 1317, 1263, 
1195, 1180, 1151, 788, 709 cm-1; HRMS-ESI: m/z calcd for C16H17N2O4 [M + H]
+ 301.1183; observed 
301.1182. 
 
(Z)-Allyl 3-(3,5-dimethyl-1H-pyrrol-2-yl)-2-(2-nitrophenyl)-acrylate ((Z)-5a): 41%, deep red 
crystalline solid; m.p. 70-72 ºC; Rf = 0.50 (80:20 petroleum spirit:acetone); 
1H NMR  (500 MHz, 
CDCl3):  2.17 (s, 3H), 2.35 (s, 3H), 4.56 (d, 2H, J = 5.5 Hz), 5.10 (dd, 1H, J = 1.5, 13.0 Hz), 5.13 (dd, 
1H, J = 1.5, 6.5 Hz),  5.79 (m, 1H), 5.90 (s, 1H), 6.82 (s, 1H), 7.43 (d, 1H, J = 7.5 Hz), 7.44 (t, 1H, J = 
7.5 Hz), 7.62 (t, 1H, J = 7.5 Hz), 8.04 (d, 1H, J = 7.5 Hz), 12.91 (br s, 1H); 13C NMR (125 MHz, 
CDCl3):  11.7, 13.8, 65.7, 111.6, 114.2, 118.1, 124.6, 124.7, 127.9, 131.5, 131.6, 132.9, 133.5, 134.4, 
137.4, 148.9, 167.3; IR (neat): ν(cm-1) = 3300, 2360, 1685, 1577, 1570, 1542, 1517, 1507, 1364, 1312, 
1182, 1144, 966, 932, 858, 790 cm-1; HRMS-ESI: m/z [M+H]+ calcd for C18H19N2O4: 327.1339, 
observed 327.1342.  
 
(E)-Allyl 3-(3,5-dimethyl-1H-pyrrol-2-yl)-2-(2-nitrophenyl)-acrylate ((E)-5b): 33%, red crystalline 
solid; m.p. 102-105 ºC; Rf = 0.40 (80:20 petroleum spirit:acetone);  
1H NMR  (500 MHz, CDCl3):  
1.95 (s, 3H), 2.19 (s, 3H), 4.59 (dd, 1H, J = 5.5, 13.5 Hz), 4.64 (dd, 1H, J = 5.5, 13.5 Hz), 5.15 (dd, 1H, 
J = 1.5, 10.0 Hz), 5.18 (dd, 1H, J = 1.5, 18.5 Hz),  5.74 (s, 1H), 5.85 (m, 1H), 6.75 (br s, 1H), 7.50 (d, 
1H, J = 8.0 Hz), 7.60 (t, 1H, J = 8.0 Hz), 7.68  (t, 1H, J = 8.0 Hz), 7.77 (s, 1H), 8.19 (d, 1H, J = 8.0 
Hz); 13C NMR (125 MHz, CDCl3):  11.5, 13.4, 65.6, 111.0, 116.3, 117.7, 123.6, 125.4, 127.6, 129.5, 
130.6, 132.5, 133.3, 133.7, 134.1, 149.4, 166.5; IR (neat): ν(cm-1) = 3455, 1687, 1610, 1557, 1524, 
1343, 1257, 1232, 1068, 869, 733 cm-1; HRMS-ESI: m/z [M+H]+ calcd for C17H19N2O4  327.1339, 
observed 327.1333. 
 
(Z)-3-(3,5-Dimethyl-1H-pyrrol-2-yl)-N-ethyl-2-(2-nitrophenyl)-acrylamide ((Z)-6a): 21%, red 
crystalline solid; m.p. 96-99 ºC; Rf = 0.17 (80:20 petroleum spirit:acetone); 
1H NMR (500 MHz, 
CDCl3):  1.07 (t, 3H, J = 7.0 Hz), 2.09 (s, 3H), 2.31 (s, 3H), 3.31 (q, 2H, J = 7.0 Hz), 5.18 (br s, 1H), 
5.82 (s, 1H), 6.46 (s, 1H), 7.52 (m, 2H), 7.65 (t, 1H, J = 8.0 Hz), 7.98 (d, 1H, J = 8.0 Hz), 12.21 (br s, 
1H); 13C NMR (125 MHz, CDCl3):  11.3, 13.5, 14.6, 34.8, 110.6, 116.4, 124.0, 124.7, 128.0, 128.7, 
128.8, 132.9, 133.3, 133.4, 136.3, 149.5, 167.5; IR (neat): ν(cm-1) = 3408, 1639, 1576, 1569, 1517, 
1457, 1350, 1224 cm-1; HRMS-ESI: m/z [M+H]+ calcd for C17H20N3O3  314.1499, observed 314.1497. 
 
(Z)-3-(3,5-Dimethyl-1H-pyrrol-2-yl)-2-(2-nitrophenyl)-N-phenylacrylamide ((Z)-7a): 22%, red 
crystalline solid; m.p. 177-179 ºC; Rf = 0.36 (80:20 petroleum spirit:acetone); 
1H NMR (500 MHz, 
CDCl3):  2.12 (s, 3H), 2.32 (s, 3H), 5.86 (s, 1H), 6.56 (s, 1H), 6.87 (br s, 1H), 7.12 (t, 1H, J = 7.5 Hz), 
7.32 (t, 2H, J = 7.5 Hz), 7.37 (t, 2H, J = 7.5 Hz), 7.56 (t, 1H, J = 8.0 Hz), 7.60 (d, 1H, J = 8.0 Hz), 7.71 
(t, 1H, J = 8.0 Hz), 8.03 (d, 1H, J = 8.0 Hz), 12.00 (br s, 1H); 13C NMR (125 MHz, CDCl3):  11.4, 
13.6, 111.1, 115.6, 121.4, 124.1, 124.9, 129.0, 129.1, 130.1, 133.5, 133.5, 133.8, 135.8, 137.4, 149.7, 
166.2; IR (neat): ν(cm-1) = 3400, 1650, 1595, 1592, 1518, 1498, 1436, 1362, 1352, 1318, 1229, 1188, 
1151, 1004, 802, 790, 772, 759, 739, 718 cm-1; HRMS-ESI: m/z [M+H]+ calcd for C21H20N3O3 
362.1499, observed 362.1521. 
 
(E)-3-(3,5-Dimethyl-1H-pyrrol-2-yl)-2-(2-nitrophenyl)-N-phenylacrylamide ((E)-7b): <5%, red 
amorphous solid  (impure, not tested in angiogenesis inhibition assay); 1H NMR (500 MHz, CDCl3):  
1.92 (s, 3H), 2.13 (s, 3H), 5.70 (s, 1H), 6.47 (br s, 1H), 7.04 (t, 1H, J = 7 Hz), 7.14 (br s, 1H), 7.24 (t, 
2H, J = 7.5 Hz), 7.43 (d, 2H, J = 8.0 Hz), 7.57 (d, 1H, J = 7.5 Hz), 7.68 (s, 1H), 7.75 (t, 1H, J = 7.5 
Hz), 7.66 (m, 1H), 8.13 (d, 1H, J = 8.0 Hz); 13C NMR (125 MHz, CDCl3):  11.2, 13.1, 110.6, 118.9, 
120.4, 123.3, 124.1, 125.1, 125.4, 128.7, 129.6, 130.3, 131.5, 133.5, 133.8, 134.3, 138.0, 149.4, 165.0. 
HRMS-ESI: m/z [M+H]+ calcd for C21H20N3O3 362.1499, observed 362.1503. 
 
(Z)-N-benzyl-3-(3,5-dimethyl-1H-pyrrol-2-yl)-2-(2-nitrophenyl)acrylamide ((Z)-8a): 16%, red 
crystalline solid; m.p. 140-142 ºC; Rf = 0.36 (80:20 petroleum spirit:acetone); 
1H NMR (500 MHz, 
CDCl3):  2.09 (s, 3H), 2.31 (s, 3H), 4.50 (d, 2H, J = 6 Hz), 5.50 (br s, 1H), 5.83 (s, 1H), 6.48 (s, 1H), 
7.20 (d, 2H, J = 8.0 Hz), 7.22 (m, 1H, J = 7.0 Hz), 7.28 (t, 2H, J = 7.5 Hz), 7.47 (m, 1H, J = 8.0 Hz), 
7.49 (m, 1H, J = 6.5 Hz), 7.61 (t, 1H, J = 7.5 Hz), 7.94 (d, 1H, J = 8.5 Hz), 12.21 (br s, 1H);  13C NMR 
(125 MHz, CDCl3):  11.3, 13.7, 43.9, 110.7, 115.8, 124.0, 124.7, 127.3, 127.3, 128.3, 128.6, 128.9, 
129.2, 133.1, 133.3, 133.4, 136.0, 138.0, 167.6; IR (neat): ν(cm-1) = 3435, 1643, 1570, 1543, 1507, 
1453, 1362, 1341, 1316, 1237, 1217, 1150, 786, 728, 709 cm-1; HRMS-ESI: m/z [M+H]+ calcd for 
C22H22N3O3 376.1656, observed 376.1668.  
 
(E)-N-benzyl-3-(3,5-dimethyl-1H-pyrrol-2-yl)-2-(2-nitrophenyl)acrylamide ((E)-8b): <5%, red 
amorphous solid  (impure, not tested in angiogenesis inhibition assay); 1H NMR (500 MHz, CDCl3):  
2.09 (s, 3H), 2.31 (s, 3H), 4.50 (d, 2H, J = 6 Hz), 5.50 (br s, 1H), 5.83 (s, 1H), 6.48 (s, 1H), 7.20 (d, 
2H, J = 8.0 Hz), 7.22 (m, 1H, J = 7.0 Hz), 7.28 (t, 2H, J = 7.5 Hz), 7.47 (m, 1H, J = 8.0 Hz), 7.49 (m, 
1H, J = 6.5 Hz), 7.61 (t, 1H, J = 7.5 Hz), 7.94 (d, 1H, J = 8.5 Hz). Note: due to impurities the chemical 
shift of the pyrrolic NH signal could not be assigned unambiguously; 13C NMR (125 MHz, CDCl3):  
11.3, 13.6, 43.9, 110.7, 115.8, 124.0, 124.7, 127.3, 127.3, 128.4, 128.6, 128.9, 129.3, 133.088, 133.3, 
133.4, 136.0, 137.974, 167.6; HRMS-ESI: m/z [M+H]+ calcd for C22H22N3O3 376.1656, observed 
376.1675. 
 
General method for condensation reactions to produce alkenes (Z)-9a, (E)-9b and (Z)-10a, (E)-
10b: Method b: Dry N,N-diisopropylamine (4.60 mmol) was dissolved in dry THF (7 mL) under Ar in 
a 3-neck 100 mL round bottom flask. The flask was cooled to -78 °C and n-butyllithium (4.60 mmol) 
was added and stirred for 20 minutes. Ethyl-2-phenylacetate 19 or ethyl-2-(2-chlorophenyl)-acetate 20 
(4.28 mmol) was then added dropwise as a solution in dry THF (1 mL) and the reaction was stirred for 
a further 30 minutes. Methyl 2-formyl-3,5-dimethyl-1H-pyrrole-1-carboxylate 12 (0.757 g, 4.18 mmol) 
was subsequently added dropwise as a solution in dry THF (1 mL) and the reaction stirred for a further 
30 min, with monitoring by TLC (75:25 petroleum spirit:EtOAc). The reaction was quenched with 
saturated aqueous NH4Cl (30 mL) and the solvent removed in vacuo. EtOAc (30 mL) was added to the 
residue and the organic layer was washed with saturated aqueous NH4Cl (3 x 25 mL), saturated 
aqueous Na2CO3 (2 x 25 mL) and brine (30 mL), before being dried over anhydrous MgSO4 and 
concentrated in vacuo. The crude product was purified by silica-gel chromatography column with a 
gradient from 100:0 to 70:30 petroleum spirit:EtOAc to provide mixtures of the (Z) and (E)-isomers. 
 
(E)-Ethyl 3-(3,5-dimethyl-1H-pyrrol-2-yl)-2-phenylacrylate ((E)-9b): 32%, yellow crystalline solid; 
m.p. 62-64 ºC; Rf = 0.43 (75:25 petroleum spirit:EtOAc); 
1H NMR (500 MHz, CDCl3):  1.26 (t, 3H, J 
= 7.0 Hz), 1.91 (s, 3H), 2.19 (s, 3H), 4.22 (q, 2H, J = 7.0 Hz), 5.69 (s, 1H), 6.84 (br s, 1H), 7.32 (d, 2H, 
J = 7.0 Hz), 7.43 (t, 1H, J = 7.0 Hz), 7.46 (t, 2H, J = 7.0 Hz), 7.75 (s, 1H); 13C NMR (125 MHz, 
CDCl3):  11.2, 13.1, 14.4, 60.5, 110.0, 120.5, 124.1, 127.4, 127.9, 128.8, 129.0, 130.2, 132.9, 137.3, 
169.2; IR (neat): ν (cm-1) = 3442, 1697, 1607, 1560, 1497, 1227 cm-1; HRMS-ESI: m/z [M+H]+ calcd 
for C17H20NO2  270.1489, observed 270.1488. 
 
(Z)-Ethyl 3-(3,5-dimethyl-1H-pyrrol-2-yl)-2-(2-chlorophenyl)-acrylate ((Z)-10a): 5%, yellow 
crystalline solid; m.p. 124-126 ºC; Rf = 0.71 (70:30 petroleum spirit:EtOAc); 
1H NMR (500 MHz, 
CDCl3):  1.20 (t, 3H, J = 7.0 Hz), 2.14 (s, 3H) 2.33 (s, 3H), 4.20 (q, 2H, J = 7.0 Hz), 5.87 (s, 1H), 6.72 
(s, 1H), 7.25 (m, 2H), 7.31 (d, 1H, J = 7.0 Hz), 7.38 (d, 1H, J = 7.0 Hz), 11.80 (br s, 1H); 13C NMR 
(125 MHz, CDCl3):  11.6, 13.8, 14.3, 61.0, 111.3, 116.1, 124.4, 126.9, 128.3, 129.2, 130.6, 131.8, 
132.2, 133.6, 135.1, 141.2, 168.9; IR (neat): ν(cm-1) = 3273, 1680, 1576, 1545, 1465, 1188, 736 cm-1; 
HRMS-ESI: m/z [M+H]+ calcd for C17H19NO2Cl  304.1099, observed 304.1099.  
 
(E)-Ethyl 3-(3,5-dimethyl-1H-pyrrol-2-yl)-2-(2-chlorophenyl)-acrylate ((E)-10b): 41%, yellow 
amorphous solid; m.p. 70-74 ºC; Rf = 0.39 (75:25 petroleum spirit:EtOAc); 
1H NMR (CDCl3, 500 
MHz):  1.24 (t, 3H, J = 7.0 Hz), 1.93 (s, 3H), 2.20 (s, 3H), 4.18 (q, 1H, J = 7.0 Hz), 4.25 (q, 2H, J = 
7.0 Hz), 5.74 (s, 1H,), 6.75 (br s, 1H), 7.3 (m, 3H), 7.54 (d, 1H, J = 8 Hz), 7.78 (s, 1H); 13C NMR (125 
MHz, CDCl3):  11.2, 13.1, 14.3, 60.6, 110.3, 117.7, 123.9, 127.3, 128.1, 129.5, 129.5, 130.1, 131.9, 
133.5, 135.1, 136.3, 167.4; IR (neat): ν(cm-1) = 3447, 1697, 1603, 1558, 1473, 1226, 745 cm-1; HRMS-
ESI: m/z [M+H]+ calcd for C17H19NO2Cl  304.1099, observed 304.1092. 
 
5.2. X-Ray Crystallography 
Crystal data Compound (Z)-5a.  C18H18N2O4, M=326.35, T=200 K, monoclinic, space group P21/c, 
Z=4, a=12.5669(4), b=7.9086(3), c=17.6200(4) Å, =103.730(2)°, V=1701.15(6) Å3, Dx=1.274 g/cm3, 
32664 reflections measured (2=5–55°) merged to 3903 unique data, R=0.053 [for 2656 data with 
I>2(I)], Rw=0.147 [all data], S=0.95.   Compound (E)-5b.  C18H18N2O4, M=326.35, T=298(2) K, 
triclinic, space group P-1, Z=2, a=8.4326(4), b=10.2147(4), c=11.0598(6) Å, =72.485(3)°, 
=76.605(2)°, =71.312(3)°, V=850.89(7) Å3, Dx=1.274 g/cm3, 7615 reflections measured (2=4–
54.2°) merged to 3674 unique data, R=0.064 [for 2849 data with I>2(I)], Rw=0.187 [all data], S=0.99. 
Structure determination Images were measured on Nonius KappaCCD diffractometers (Mo K 
radiation, graphite monochromator, =0.71073 Å) and data were extracted using the DENZO 
package.[26]  For (Z)-5a, structure solution was by direct methods (SIR92)[27] and the structure was 
refined using the CRYSTALS program package.[28]  For (E)-5b, structure solution was by direct 
methods (SIR97)[29] and the structure was refined using the SHELXL-97 program package.[30] Atomic 
coordinates, bond lengths and angles and displacement parameters have been deposited at the 
Cambridge Crystallographic Data Centre (CCDC accession numbers 905343 and 905344, 
respectively). These data can be obtained free-of-charge via www.ccdc.cam.ac.uk/data_requerst/cif, by 
emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data 
Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033. 
 
5.3. Angiogenesis Inhibition Assay 
Compounds were tested for angiogenesis inhibition in 48-well culture plates using the previously 
reported in vitro assay with some modifications.[23] Briefly, the thoracic aortas from female Fischer 344 
rats were excised and the 2.5cm long vessels placed in HBSS media containing 2.5 µg/mL 
amphotericin B and cross-sectioned at 1mm intervals. In the angiogenesis assay 15 µL of bovine 
thrombin (50 NIH unit/mL in 0.15 M NaCl) was added to each well, followed by 0.5 mL/well of 3 
mg/mL bovine fibrinogen in Medium 199. The thrombin and fibrinogen were mixed rapidly and one 
vessel section was quickly placed in the center of the well before clot formation. Fibrin gel formation 
usually occurred within 0.5 min leaving the vessel fragment suspended in the gel. Upon gel formation, 
0.5 mL/well of Medium 199 supplemented with 20% FCS, 0.1% ε-amino caproic acid, L-glutamine, 
and antibiotics (gentamicin sulphate and amphotericin B) and test compound were added.  Six replicate 
cultures were examined for each concentration of test compound. Vessels were cultured at 37 ºC in 5% 
CO2 in a humidified environment for 7 days, with the medium being changed on Day 4. On Day 5 the 
percentage of the field of view occupied by vessel outgrowths (FOV occupancy %) was used as a 
quantitative measure of angiogenesis (inhibition) relative to control (no compound added). 
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